Stocktoria
ALX ONCOLOGY HOLDINGS INC ALXO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-07-17
ALX ONCOLOGY HOLDINGS INC financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $1.2M | $4.8M |
| R&D expense | $77.0M | $116.4M | $141.8M | $98.4M | $60.2M | $29.0M | $16.3M |
| Operating income | -$104.0M | -$142.5M | -$170.3M | -$127.4M | -$83.6M | -$43.7M | -$19.2M |
| Interest expense | $1.6M | $1.7M | $1.6M | $238,000 | $13,000 | — | — |
| Income tax | $0 | $0 | $0 | $64,000 | -$21,000 | $241,000 | $34,000 |
| Net income | -$101.7M | -$134.8M | -$160.8M | -$123.5M | -$83.5M | -$45.7M | -$19.2M |
| EPS (diluted) | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-2.76 | — |
| Operating cash flow | -$84.1M | -$121.9M | -$130.4M | -$89.2M | -$68.1M | -$38.3M | -$14.2M |
| Free cash flow | -$84.4M | -$122.4M | -$131.6M | -$90.7M | -$68.8M | -$38.3M | -$14.6M |
| Cash & equivalents | $16.4M | $17.6M | $22.4M | $48.8M | $363.7M | $434.2M | $9.0M |
| Total assets | $59.0M | $147.8M | $242.6M | $306.5M | $380.2M | $436.1M | $10.7M |
| Total liabilities | $33.1M | $34.2M | $52.8M | $43.0M | $17.1M | $6.2M | $11.0M |
| Shareholders' equity | $26.0M | $113.6M | $189.7M | $263.5M | $363.0M | $429.8M | -$70.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | -100.0% | -75.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.